XML 55 R26.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborative Arrangements and Licensing Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Biogen [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with Biogen |  | $ | 350,146 |  |  | $ | 366,696 |  |  | $ | 428,784 |
Percentage of total revenue |  |  | 44 | % |  |  | 62 | % |  |  | 53 | %
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with AstraZeneca |  | $ | 202,236 |  |  | $ | 79,160 |  |  | $ | 254,591 |
Percentage of total revenue |  |  | 26 | % |  |  | 13 | % |  |  | 31 | %
GSK [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with GSK (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with GSK |  | $ | 15,000 |  |  | $ | — |  |  | $ | — |
Percentage of total revenue |  |  | 2 | % |  |  | 0 | % |  |  | 0 | %
Novartis [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Novartis (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with Novartis |  | $ | 30,194 |  |  | $ | 237 |  |  | $ | 25,526 |
Percentage of total revenue |  |  | 4 | % |  | Less than 1% |  |  |  | 3 | %
Otsuka [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the year ended December 31, 2023, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amount):
|  | Year Ended December 31, |
|  | 2023 |
Revenue from our relationship with Otsuka |  | $ | 56,480 |
Percentage of total revenue |  |  | 7 | %
Roche [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with Roche |  | $ | 48,838 |  |  | $ | 67,202 |  |  | $ | 17,241 |
Percentage of total revenue |  |  | 6 | % |  |  | 11 | % |  |  | 2 | %
Sobi [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our distribution agreement with Sobi for TEGSEDI in North America (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
TEGSEDI revenue from our distribution agreement with Sobi in North America |  | $ | 2,646 |  |  | $ | 4,004 |  |  | $ | 7,443 |
Percentage of total revenue |  | Less than 1% |  |  |  | 1 | % |  |  | 1 | %
Alnylam [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Alnylam (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Revenue from our relationship with Alnylam |  | $ | 28,426 |  |  | $ | 21,389 |  |  | $ | — |
Percentage of total revenue |  |  | 4 | % |  |  | 4 | % |  |  | 0 | %

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_GlaxoSmithKlineCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_NovartisCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_OtsukaPharmaceuticalCoLtdCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RocheCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_SwedishOrphanBiovitrumABDistributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |